Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.85% | 9.88% | 12.59% | 20.91% | 17.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.85% | 9.88% | 12.59% | 20.91% | 17.67% |
| Cost of Revenue | 6.89% | 17.25% | 26.91% | 39.17% | 32.55% |
| Gross Profit | 1.54% | 4.49% | 3.07% | 9.39% | 8.37% |
| SG&A Expenses | 1.83% | 3.60% | 9.30% | 22.46% | 37.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.23% | 6.70% | 14.37% | 27.88% | 33.18% |
| Operating Income | 16.96% | 14.40% | -30.10% | -127.56% | -1,443.57% |
| Income Before Tax | 63.72% | 24.16% | -68.06% | -249.83% | -1,346.75% |
| Income Tax Expenses | 108.99% | 1.18% | 134.11% | -79.58% | -190.93% |
| Earnings from Continuing Operations | 50.45% | 27.09% | -200.05% | -431.64% | -589.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.45% | 28.99% | -183.89% | -380.79% | -607.86% |
| EBIT | 16.96% | 14.40% | -30.10% | -127.56% | -1,443.57% |
| EBITDA | 27.01% | 25.79% | -15.59% | -120.79% | -3,268.31% |
| EPS Basic | 49.72% | 25.69% | -192.94% | -391.95% | -601.13% |
| Normalized Basic EPS | 45.83% | 23.63% | -64.74% | -229.73% | -1,511.76% |
| EPS Diluted | 43.65% | 24.14% | -191.19% | -360.61% | -978.85% |
| Normalized Diluted EPS | 45.83% | 25.42% | -57.67% | -201.23% | -2,500.00% |
| Average Basic Shares Outstanding | -3.45% | -2.89% | -1.67% | -0.57% | 0.57% |
| Average Diluted Shares Outstanding | -3.12% | -5.39% | -5.21% | -4.16% | -3.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |